Abstract
Recessive mutations in PRKN, PARK7 and PINK1 are established causes of early-onset Parkinson’s disease (EOPD). Previous studies have interrogated the role of heterozygous variants in these genes but mainly focused on rare (minor allele frequency [MAF] <1%) damaging variants or established mutations. Here, we assessed heterozygous private PRKN, PARK7 and PINK1 variants in PD risk in four large-scale PD case-control datasets by performing gene-wise burden analyses using sequencing data totaling 5,829 PD cases and 7,221 controls, and summary allele counts from 9,501 PD cases and 48,207 controls. Results showed no significant burden in all three genes after meta-analyses. Burden in EOPD (age at onset <50 years) and late-onset PD (≥50 years) remained nonsignificant. In summary, we found no evidence to support the association of the excess burden of heterozygous private variants in PRKN, PARK7, and PINK1 with PD risk in the European population. Larger, more diverse cohorts are needed to accurately determine their role in PD.
Competing Interest Statement
Z.G.O is on the Scientific Advisory Board of Bial Biotech Inc. and Handl Therapeutics, and received consultancy fees from Bial Biotech Inc., Handl Therapeutics (UCB), Denali, Neuron23, Ono Therapeutics, Prevail Therapeutics, Idorsia, Guidepoint and Lighthouse. D.K. is the Founder and Scientific Advisory Board Chair of Lysosomal Therapeutics Inc. and Vanqua Bio. D.K. serves on the scientific advisory boards of The Silverstein Foundation, Intellia Therapeutics, AcureX and Prevail Therapeutics and is a Venture Partner at OrbiMed. J.H., C.H.W., D.S., E.A.F., E.Y., F.A., L.K., P.S., R.N.A., S.H.B., B.R.Z., B.I.B. and S.J.L. declare that they have no competing interests.
Funding Statement
The analysis of cohorts at McGill University was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. Z.G.O. is supported by the Fonds de recherche du Quebec - Sante (FRQS) Chercheurs-boursiers award and is a William Dawson Scholar. D.K. is supported by the Simpson Querrey Center for Neurogenetics. The research of C.H.W. is supported by Neuraly, the consulting fee is supported by Kyowa, Sunovion, Acadia and Abbvie, and the speaker's honoraria is supported by Adamas, Amneal, Kyowa and Neurocrine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All genetic data used in this study is available (upon application) from the following sites: (i) Accelerating Medicines Partnership: Parkinson's Disease (https://amp-pd.org). (ii) International Parkinson's Disease Genomics Consortium (https://pdgenetics.org/resources). (iii) Parkinson's Disease Variant Browser (https://pdgenetics.shinyapps.io/VariantBrowser). (iv) Dataset using targeted next-generation sequencing with Molecular inversion probes (https://cbigr-open.loris.ca/). The details of the IRB/oversight body that provided approval or exemption for the research described are given below: As analyses utilize secondary analyses of suitably anonymized datasets, they do not require ethics committee review. The respective ethical committees for medical research approved involvement in genetic studies and all participants gave written informed consent in the original publications for the datasets used. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All genetic data used in this study is available (upon application) from the following sites: (i) Accelerating Medicines Partnership: Parkinson's Disease (https://amp-pd.org). (ii) International Parkinson's Disease Genomics Consortium (https://pdgenetics.org/resources). (iii) Parkinson's Disease Variant Browser (https://pdgenetics.shinyapps.io/VariantBrowser). (iv) Dataset using targeted next-generation sequencing with Molecular inversion probes (https://cbigr-open.loris.ca/)
